News | Clinical Decision Support | March 11, 2015

Point of Care Decision Support Anticoagulation Software Helps Reduce Hospital Re-Admissions

Software is designed and developed in association with national patient safety guidelines to reduce adverse events and re-admissions

Point of Care Decision Support, anticoagulation software, PCDS AC, therapy

Image courtesy of Point of Care Decision Support

March 11, 2015 — Point of Care Anticoagulation software (PCDS AC) optimizes delivery of anticoagulation (AC) drugs and reduces adverse events associated with anticoagulation therapy. The software was designed and developed in collaboration with leading clinical thrombosis experts, and is a decision support tool that takes the complexity out of AC management by providing a real-time AC dashboard. With intuitive, predictive clinical decision support, PCDS AC transforms evidence-based guidelines into intelligent tools that measure and improve AC therapy outcomes.

PCDS AC meets the key recommendations of The Joint Commission, the Centers for Medicare and Medicaid Services (CMS) and the Anticoagulation EHR (Electronic Health Record) Task Force. The system could be beneficial in light of new target-specfic oral anticoagulants (TSOAC) drugs coming onto the market, changing AC therapy protocols and more stringent regulatory guidelines.

Key benefits and outcomes of using PCDS AC include:

Patient Safety and Cost Savings: Warfarin-related adverse drug events (myocardial infarctions, strokes, major bleeds, etc.) are reduced by consistently achieving time-in-therapeutic range (TTR) above 70 percent per CMS recommendations.

Patient Safety & Revenue Generation: The PCDS AC system brings together the ACCP Antithrombotic guidelines, risk ratings like CHA2DS2-VASc, HAS-BLED, HEMORR2HAGES, drug-drug interactions, and other evidence-based research to automatically identify high risk patients and manage their AC care end-to-end.  This also provides an opportunity to identify new patients who may benefit from proactive AC therapy and reduce their overall risk of stroke.

Patient Satisfaction: The PCDS AC system incorporates full TSOAC therapy and workflow, which allow for expanded paradigms of anticoagulant management. These new TSOAC agents require far less blood testing, which is a major benefit for patients.  In addition, the system provides data on the efficacy of TSOACs, leading to improved patient care and, ultimately, cost savings surrounding adverse events.

Fulfill CMS Meaningful Use Stages 2 & 3: Provides ability to fulfill CMS MU-2 criteria for quality of Warfarin dosing at a system level with TTR > 70 percent.  Achieves MU-3 measures by improving population health, provides decision support for high priority health conditions, and provides patient self-management tools via a mobile patient engagement application.

Point of Care Decision Support provides any healthcare organization a free, customized demonstration and business case report for its anticoagulant patient population. 

For more information: www.ptofcare.com

Related Content

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
New FOURIER Analysis Examines How Low Cholesterol Can Safely Go
News | ESC| September 12, 2017
September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressive
CANTOS Study Shows Reducing Inflammation Cuts Cardiovascular Disease, Lung Cancer Risk
News | ESC| September 12, 2017
September 12, 2017 — The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk b
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies| September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
Overlay Init